RT Journal Article
T1 Current status of FRIDA, diffraction limited NIR Instrument for the GTC
A1 Cardiel López, Nicolás
A1 Eliche Moral, María del Carmen
A1 Pascual, Sergio
AB FRIDA (inFRared Imager and Dissector for the Adaptive optics system of the Gran Telescopio Canarias) is designed as a diffraction limited instrument that will offer broad and narrow band imaging and integral field spectroscopy capabilities with low (R similar to 1,500), intermediate (R similar to 4,500) and high (R similar to 30,000) spectral resolutions to operate in the wavelength range 0.9 - 2.5 mu m. The integral field unit is based on a monolithic image slicer. The imaging and IFS observing modes will use the same Teledyne 2K x 2K detector. FRIDA will be based at the Nasmyth B platform of GTC, behind the AO system. The key scientific objectives of the instrument include studies of solar system bodies, low mass objects, circumstellar outflow phenomena in advanced stages of stellar evolution, active galactic nuclei, high redshift galaxies, resolved stellar populations, semi-detached binary systems, young stellar objects and star forming environments. FRIDA is a collaborative project between the main GTC partners, namely, Spain, Mexico and Florida. In this paper, we present the status of the instrument design as it is currently being prepared for its manufacture, after an intensive prototypes' phase and design optimization. The CDR was held in September 2011.
PB SPIE-Int Soc Optical Engineering
SN 0277-786X
YR 2012
FD 2012
LK https://hdl.handle.net/20.500.14352/44431
UL https://hdl.handle.net/20.500.14352/44431
LA eng
NO © 2012 SPIE. Conference on Ground-Based and Airborne Telescopes (IV. 2012. Amsterdam, Netherlands). We are grateful to Grupo Santander (Spain) through Encuentros Astrofísicos Blas Cabrera (UNAM-IAC) and our home institutions for their support. We also gratefully acknowledge partial funding for this project through generous grants from PAPITT-UNAM (grant IT116311) and CONACYT grant INFR-2009-01-122664).
NO PAPITT-UNAM
NO CONACYT
DS Docta Complutense
RD 25 abr 2025